Dr.ย Neerajย Agarwal
MD, FASCO
Professor of Medicine & Director, GU Oncology Program
corporate_fareHuntsman Cancer Institute, University of Utah, Salt Lake City
Neeraj Agarwal
MD, FASCO
Dr. Neeraj Agarwal is a Professor of Medicine, Presidential Endowed Chair of Cancer Research, and Director of the Genitourinary Oncology Program at Huntsman Cancer Institute, University of Utah โ an NCI-designated comprehensive cancer centre. He is internationally recognised as a rising global key opinion leader in prostate, kidney, and bladder cancer, and serves as a Fellow of the American Society of Clinical Oncology (FASCO).
Trained at the All India Institute of Medical Sciences (AIIMS) in New Delhi and subsequently at the University of Iowa and Huntsman Cancer Institute, Dr. Agarwal has spent over 15 years building one of the most prolific clinical trial programmes in genitourinary oncology. He has served as study chair or steering committee member for pivotal trials leading to FDA and EMA approvals of apalutamide, olaparib, and talazoparib in metastatic prostate cancer, and has authored more than 500 peer-reviewed publications, book chapters, and abstracts. In addition to his clinical and research leadership, he is Chief Editor of ASCO Daily News, a panel member on NCCN, ESMO, and ASCO guidelines committees for GU cancers, and an advisor to the FDA Oncology Drug Advisory Committee. Patients consistently highlight his clarity in communicating complex treatment plans and his commitment to maintaining quality of life throughout advanced cancer care.
CancerFax can coordinate medical-record review and consultation support for international patients seeking a second opinion or treatment access with Dr. Agarwal at Huntsman Cancer Institute, subject to availability.
Why Consider Dr. Neeraj Agarwal?
Dr. Agarwal combines landmark trial leadership, biomarker-driven clinical practice, and a deeply compassionate approach โ giving advanced genitourinary cancer patients access to the very therapies that are reshaping global standards of care.
Areas of Specialisation
Focused expertise in genitourinary cancers โ prostate, kidney, and bladder โ with particular depth in biomarker-driven systemic therapy and clinical trial-based treatment.
Dr. Agarwal's practice covers the full spectrum of genitourinary malignancies, with primary expertise in advanced prostate cancer including metastatic hormone-sensitive and castration-resistant disease, renal cell carcinoma, and urothelial cancers of the bladder and upper tract.
Advanced Prostate Cancer
Comprehensive management of localised, recurrent, metastatic hormone-sensitive, and metastatic castration-resistant prostate cancer using the latest systemic agents and clinical trial options.
- arrow_rightEnzalutamide and apalutamide for hormone-sensitive and castration-resistant disease
- arrow_rightAbiraterone-based regimens in metastatic prostate cancer
- arrow_rightDarolutamide and emerging next-generation AR inhibitors
- arrow_rightTalazoparib plus enzalutamide (TALAPRO-2 trial, lead author)
- arrow_rightOlaparib and niraparib in HRR gene-mutated mCRPC
- arrow_rightBiomarker-driven PARP inhibitor selection using HRR gene status
- arrow_rightRadium-223 for bone-metastatic castration-resistant prostate cancer
- arrow_rightLutetium-177-PSMA radioligand therapy
- arrow_rightActinium-225-based therapies under investigational protocols
Kidney Cancer (Renal Cell Carcinoma)
Systemic management of localised and metastatic renal cell carcinoma, including clear-cell and non-clear-cell subtypes, using TKIs, checkpoint inhibitors, and combination regimens.
- arrow_rightCabozantinib and other TKIs for metastatic RCC
- arrow_rightCheckpoint inhibitor combinations (e.g., nivolumab plus cabozantinib)
- arrow_rightTreatment sequencing across lines of therapy in advanced RCC
Bladder & Urothelial Cancer
Medical oncology management of bladder and upper tract urothelial cancers, including checkpoint inhibitor-based and targeted-therapy approaches.
- arrow_rightPembrolizumab and other checkpoint inhibitors in metastatic bladder cancer
- arrow_rightEnfortumab vedotin and emerging antibody-drug conjugates
- arrow_rightPlatinum-based chemotherapy and sequencing in locally advanced and metastatic disease
Procedures & Treatments Performed
Systemic, targeted, and investigational treatments for genitourinary cancers
As a medical oncologist, Dr. Agarwal focuses on systemic treatments for genitourinary malignancies. His practice incorporates the latest AR-targeted agents, PARP inhibitors, immunotherapy, radiopharmaceuticals, and clinical trial-based therapies, guided by molecular profiling and biomarker assessment.
Hormonal & AR-Targeted Therapy
Medical OncologyEvidence-based hormonal and androgen receptor-targeted therapies across the full spectrum of prostate cancer disease states.
PARP Inhibitor Therapy
Targeted TherapyPrecision therapy using PARP inhibitors for patients with HRR gene alterations in metastatic prostate cancer, including landmark combination regimens.
Immunotherapy
Targeted TherapyCheckpoint inhibitor therapy for eligible patients with bladder cancer, renal cell carcinoma, and biomarker-selected prostate cancer.
Radiopharmaceutical Therapy
Medical OncologyRadioligand and radiopharmaceutical therapies for advanced prostate cancer, including established agents and investigational protocols.
Clinical Trial Enrolment
Second OpinionEligibility assessment and enrolment in phase IโIII clinical trials through Huntsman Cancer Institute's Center of Investigational Therapeutics, directed by Dr. Agarwal.
Second Opinion & Complex Case Review
Second OpinionSpecialist review of complex or refractory genitourinary cancer cases, including patients who have progressed on standard therapy or require assessment for clinical trial eligibility.
Research & Publications
Over 500 peer-reviewed contributions shaping global genitourinary oncology standards
Dr. Agarwal is one of the most published clinical investigators in genitourinary oncology, with more than 500 peer-reviewed articles, book chapters, and abstracts. His research spans pivotal phase III trials, PARP inhibitor combinations, biomarker development, and radiopharmaceutical therapy, with findings directly informing NCCN, ESMO, and ASCO guidelines.
A full publication list is available on PubMed and Dr. Agarwal's institutional profile at Huntsman Cancer Institute. CancerFax can support patients in assessing eligibility for relevant ongoing trials.
Education & Training
Dr. Agarwal completed his foundational medical training at the All India Institute of Medical Sciences (AIIMS), New Delhi โ one of India's most prestigious medical institutions โ before pursuing advanced postgraduate training in the United States across internal medicine, geriatric medicine, and haematology-oncology fellowships.
Clinical Experience
Dr. Agarwal has spent his entire post-fellowship career at Huntsman Cancer Institute, University of Utah, where he has progressively risen to hold multiple senior leadership roles across clinical, research, and educational domains over more than 15 years.
Languages & International
Dr. Agarwal consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Agarwal's team.
CancerFax can coordinate professional medical interpreter support for international patients requiring assistance in other languages.
How CancerFax Helps You Access Dr. Neeraj Agarwal
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Neeraj Agarwal's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Neeraj Agarwal's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Neeraj Agarwal before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Neeraj Agarwal's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Neeraj Agarwal's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Neeraj Agarwal's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Neeraj Agarwal
Dr. Agarwal is a genitourinary medical oncologist specialising in prostate cancer โ including metastatic hormone-sensitive and castration-resistant prostate cancer โ as well as kidney cancer (renal cell carcinoma) and bladder and urothelial cancers. He leads the GU Oncology Program at Huntsman Cancer Institute, University of Utah.
Huntsman Cancer Institute treats patients from across the United States and, in selected cases, from other countries. CancerFax can coordinate medical-record review and consultation support for international patients seeking an opinion or treatment access with Dr. Agarwal, subject to hospital availability and case acceptance. Please submit your reports through CancerFax to begin the process.
Submit your medical reports โ including pathology, imaging, molecular profiling results, and treatment history โ through CancerFax. The CancerFax team will review the documents, prepare a structured case summary, and coordinate the next steps with Huntsman Cancer Institute, subject to availability. For patients already in the United States, appointments can also be requested directly through the University of Utah Health website.
Dr. Agarwal has served as study chair or steering committee member for multiple landmark phase III trials, including TALAPRO-2 (talazoparib plus enzalutamide) and trials leading to FDA approvals of apalutamide and olaparib. As Director of the Center of Investigational Therapeutics at HCI, he also designs and leads early-phase trials. Eligible patients treated by Dr. Agarwal may be assessed for enrolment in ongoing clinical trials at Huntsman Cancer Institute.
Dr. Agarwal uses a broad range of systemic therapies including enzalutamide, apalutamide, abiraterone, PARP inhibitors (talazoparib, olaparib, niraparib), radiopharmaceuticals (radium-223, lutetium-177, actinium-225 under trial), and immune checkpoint inhibitors. Treatment selection is guided by disease stage, prior therapy, and molecular biomarkers including HRR gene status, SPOP, and HSD3B1.
Dr. Agarwal's leadership of pivotal trials that led to multiple FDA and EMA drug approvals, his authorship of more than 500 peer-reviewed publications, and his roles on NCCN, ESMO, and ASCO guidelines panels collectively position him at the forefront of global prostate cancer management. He is also Chief Editor of ASCO Daily News and an advisor to the FDA Oncology Drug Advisory Committee, meaning he plays an active role in shaping international treatment standards.
As an oncologist of Indian origin trained at AIIMS New Delhi, Dr. Agarwal is particularly well known to patients and physicians from India seeking expert prostate cancer care in the United States. CancerFax supports Indian patients and families in understanding their options and, where appropriate, coordinating case review and consultation access with Dr. Agarwal's team at Huntsman Cancer Institute.
Connect with Neeraj Agarwal Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.